| Budget Amount *help |
¥2,500,000 (Direct Cost: ¥2,500,000)
Fiscal Year 2004: ¥1,300,000 (Direct Cost: ¥1,300,000)
Fiscal Year 2003: ¥1,200,000 (Direct Cost: ¥1,200,000)
|
|---|
| Research Abstract |
Cysteinyl Leukotrienes (CysLTs) induce contraction of the tracheal muscle. However, the effect of CysLTs on monocytes/macrophages is poorly understood.
We examined the production of tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), IL-2, IL-4, IL-6, IL-8, IL-10, monocyte chemoattractant protein 1 (MCP-1), macrophage inflammatory protein 1-β (MIP-1β) macrophage-colony stimulating factor (M-CSF), and eotaxin induced by CysLTs (LTC4, -D4, and -E4) in THP-1 cells, a human monocytic leukemia cell line, and peripheral blood CD14+ monocytes/macrophages. Cells were exposed to LTC4, -D4, or -E4. Some samples were pretreated with pranlukast, a CysLT1 receptor antagonist, for 30 min before the addition of CysLTs. Supernatant fluid, both before and after the addition of CysLTs, was harvested for determination of cytokine levels.
CysLTs induced MCP-1 and MIP-1β in THP-1 cells and peripheral blood CD14+ monocytes/macrophages, but not other cytokines. PCR demonstrated that CysLTs increased MCP-1 mRNA expression in THP-1 cells. Moreover, we demonstrated that pranlukast, a CysLT1 receptor antagonist, inhibits MCP-1 and MIP-1β productions by CysLTs in THP-1 cells and peripheral blood CD14+ monocytes/macrophages.
CysLTs induce MCP-1 and MIP-1β in human monocytes/macrophages.
|
